gern buy idea with stop shown in the graphgern buy idea with stop shown in the graph
we must keep the stop as shown in the graph
GERN
Geron's Imetelstat Receives FDA Advisors' BackingGeron Corporation's ( NASDAQ:GERN ) blood disorder drug, Imetelstat, has received a crucial vote of confidence from advisers to the U.S. Food and Drug Administration (FDA). Despite initial concerns raised by the agency's staff regarding data clarity and safety issues, the advisory panel overwhelmingly backed the benefits of Imetelstat for treating transfusion-dependent anemia in patients with myelodysplastic syndromes (MDS), a group of blood cancers.
The panel's resounding endorsement of Imetelstat, by a wide 12-to-2 margin, underscores the drug's potential to address an unmet medical need in a patient population with limited treatment options. While acknowledging the associated risks and toxicities of the treatment, panelists emphasized that these appear to be manageable, particularly in the context of the severity of MDS and the scarcity of effective therapies.
Geron's pursuit of FDA approval for Imetelstat represents a significant milestone for the company, marking its potential entry into the commercial treatment market. If approved, Imetelstat will compete with Bristol Myers Squibb's Reblozyl, which received FDA approval last year for the same disease indication. Analysts project substantial market opportunity for Imetelstat, with estimates suggesting potential sales of $933 million by 2029, underscoring the drug's commercial potential and the sizable unmet need it aims to address.
Despite concerns raised by the FDA regarding the lack of additional benefits beyond the primary study goal of increasing transfusion independence, Geron ( NASDAQ:GERN ) remains optimistic about Imetelstat's prospects. The company asserts that transfusion independence serves as the regulatory gold standard for approvals in this patient setting, highlighting the significance of achieving this milestone in the drug's development.
The panel's endorsement of Imetelstat represents a significant step forward in the quest to advance treatment options for patients with MDS-related anemia. With the potential to provide a much-needed therapeutic option for a vulnerable patient population, Imetelstat stands poised to make a meaningful impact in the field of hematology, offering hope to patients and caregivers alike.
As Geron awaits the FDA's final decision on Imetelstat, the company remains committed to advancing the development of innovative therapies to address critical unmet needs in hematologic disorders. With Imetelstat on the cusp of potential approval, Geron looks forward to realizing its mission of transforming the treatment landscape for patients battling blood disorders.
GERN: Daily VCPSetup: Rocketbase
VCP: 5W 39/6 4T
RS: 98
The posted chart contains a VCP (volatility contraction pattern). The first label "W" stands for weekly and shows the duration of the entire consolidation. In the middle label, the percentage of contractions is indicated (for example, "15/4"), with 15 representing the -15% depth of the base and 4 representing -4% of the last contraction. The last part "T" represents the number of contractions. The light blue lines in the chart correspond to the contractions. A more detailed description can be found in Mark Minervini's books.
RS stands for relative strength and measures the strength of the stock compared to the overall market. The value range is 1-99 with 99 being the highest value. The rank was generated by fyntrade.
GERN for a swingshort term resistance seen but the daily support is very good. so a bounce from daily support should take it to the 5$ mark
Geron Corporation in recovery. GERNB or X Wave. Recovery within a recovery.
This is a reflection using technical analysis + only and we do not consider valuation and macro factors at this stage.
The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe!
GERN - DIAMOND TOP/BOTTOM - BULLISH MOVEAll, this chart sucks in all honestly, but think we are looking at a reversal here, needs to hold exact level it's at before moving up or may drop down one level bounce and should break out the top. Either way WW this week/next.
Long | GERNNASDAQ:GERN
Possible Scenario: LONG
Evidence: Price Action
This is my idea and could be wrong 100%
* It's a good buy opportunity right now, and it's ready to fly soon.
GERN - looks like it's breaking outThis one has a nice impulse up and it starting to look like it will continue that move. Once breaking out of the larger degree structure it looks like some positive buying is happening now.
GERN GERN, waiting for the breakkout I highlight this lateral phase that has lasted for several months, within what seems to me a triangle in which the title has already passed the half of the figure
GERN : A Small for every size of Pot. :)New management, improvement in balance sheets convinced me. Sector is also outperforming. And now cup with handle pattern setup on chart. Looks like There is a strong resistance at current price, But I'm bullish. Target price = $4.5.
OPENING: GERN OCT 19TH 4 MONIED COVERED CALL... for a 3.22 debit.
Max Profit: $78/contract
Max Loss/Buying Power Effect: $322 per contract
Break Even/Cost Basis: 3.22/share
Notes: A speculative shot on a high implied volatility biotech underlying ... .
Bullish on GERN9 year channel
another attempt at breaking resistance
If we can break resistance, price tgt: $10+
"Holy Grail" buy on the weekly (Linda Rashke pattern)Market retreats to 20 period EMA after making new highs (for long positions)/lows (for shorts) with ADX (14period) >30. Some people use the 20 period SMA. Projection is a retest of the highs. Trailing stop. Failed grails tend to move (painfully) in the opposite direction.
$GERN Looking at uptrend.After the last few days of consolidation we find that GERN has broken its down trend with slight confirmation at a new uptrend. With that in mind the beginning of may should hold some value as data starts to surface and a shareholders meeting is set to take place around the 15th of May.
This is a long-term play with a lot of upside potential. Looking for a strong breakout. First target price is 5.25 followed by 5.80. This is conservative and I ask that everyone continue to remember that short volume is high, if margins need to cover this thing could break out strong to the upside. Continue to watch for developments.
Proud to see it holding solid above 4.00$ as of the time of this post. Looking for breakout above moving average to find new support, however, we seem to find solid support at the 4.00$ price point (for now.)
Hold.
GERN potential break outPlaying safe: buy stop order just above consolidation range. Break out catalyst: earnings report. Target as shown.
GERN long ideasGERN looks ready to rebound off its recent low of 2.65, stoc went it's 30 and a bullish continuation seems to be forming
Volume on downtrend as well as current reversal is low however and should be preceded with exercised caution
